Serum oncoproteins and growth factors in asbestosis and silicosis patients

P. W. Brandt-Rauf, S. Smith, K. Hemminki, H. Koskinen, H. Vainio, H. Niman, J. Ford

Research output: Contribution to journalArticle

Abstract

Levels of 9 different oncoproteins and growth factors were assayed by immunoblotting with monoclonal antibodies in 91 serum samples collected between March 1983 and August 1987 from 46 pneumoconiosis patients (36 asbestosis, 10 silicosis) at high risk for the development of cancer. Follow-up of these patients through June 1991 showed that 18 had developed cancer (11 lung, 2 pleural mesothelioma, 2 transitional-cell carcinomas of the urinary bladder, 1 osteosarcoma, 1 non-Hodgkin's lymphoma, 1 adenocarcinoma of the gallbladder). Increased serum levels of ras oncogene-related protein (p21) were found in 7 of the 18 patients who developed cancer (5 lung, 2 pleural mesothelioma) versus 2 of the 28 patients without cancer, a statistically significant difference (p = 0.012). In addition, 6 of the 7 p21-positive cancer cases had positive serum samples prior to clinical diagnosis of disease (average = 16.3 months, range = 3-26 months prior to diagnosis), suggesting that elevated serum p21 levels may be a useful marker for earlier detection in a significant percentage of respiratory malignancies. Finally, elevated serum levels of PDGF-related protein were detected significantly more frequently in advanced pneumoconiosis cases (ILO radiographic classification of 2/1 or greater) than in less advanced cases (80% vs. 41.9%; p = 0.016), and there was a tendency for these PDGF-positive patients to have progression of their disease (68.2% vs. 41.7%; p = 0.065), suggesting that elevated serum PDGF levels may be a marker for the development of severe and progressive pneumoconioses.

Original languageEnglish (US)
Pages (from-to)881-885
Number of pages5
JournalInternational Journal of Cancer
Volume50
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Asbestosis
Silicosis
Oncogene Proteins
Intercellular Signaling Peptides and Proteins
Pneumoconiosis
Serum
Mesothelioma
Oncogene Protein p21(ras)
Lung Neoplasms
Neoplasms
Transitional Cell Carcinoma
Osteosarcoma
Gallbladder
Immunoblotting
Non-Hodgkin's Lymphoma
Disease Progression
Urinary Bladder
Adenocarcinoma
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brandt-Rauf, P. W., Smith, S., Hemminki, K., Koskinen, H., Vainio, H., Niman, H., & Ford, J. (1992). Serum oncoproteins and growth factors in asbestosis and silicosis patients. International Journal of Cancer, 50(6), 881-885.

Serum oncoproteins and growth factors in asbestosis and silicosis patients. / Brandt-Rauf, P. W.; Smith, S.; Hemminki, K.; Koskinen, H.; Vainio, H.; Niman, H.; Ford, J.

In: International Journal of Cancer, Vol. 50, No. 6, 1992, p. 881-885.

Research output: Contribution to journalArticle

Brandt-Rauf, PW, Smith, S, Hemminki, K, Koskinen, H, Vainio, H, Niman, H & Ford, J 1992, 'Serum oncoproteins and growth factors in asbestosis and silicosis patients', International Journal of Cancer, vol. 50, no. 6, pp. 881-885.
Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H et al. Serum oncoproteins and growth factors in asbestosis and silicosis patients. International Journal of Cancer. 1992;50(6):881-885.
Brandt-Rauf, P. W. ; Smith, S. ; Hemminki, K. ; Koskinen, H. ; Vainio, H. ; Niman, H. ; Ford, J. / Serum oncoproteins and growth factors in asbestosis and silicosis patients. In: International Journal of Cancer. 1992 ; Vol. 50, No. 6. pp. 881-885.
@article{37155741068248d094f6966ea19b9885,
title = "Serum oncoproteins and growth factors in asbestosis and silicosis patients",
abstract = "Levels of 9 different oncoproteins and growth factors were assayed by immunoblotting with monoclonal antibodies in 91 serum samples collected between March 1983 and August 1987 from 46 pneumoconiosis patients (36 asbestosis, 10 silicosis) at high risk for the development of cancer. Follow-up of these patients through June 1991 showed that 18 had developed cancer (11 lung, 2 pleural mesothelioma, 2 transitional-cell carcinomas of the urinary bladder, 1 osteosarcoma, 1 non-Hodgkin's lymphoma, 1 adenocarcinoma of the gallbladder). Increased serum levels of ras oncogene-related protein (p21) were found in 7 of the 18 patients who developed cancer (5 lung, 2 pleural mesothelioma) versus 2 of the 28 patients without cancer, a statistically significant difference (p = 0.012). In addition, 6 of the 7 p21-positive cancer cases had positive serum samples prior to clinical diagnosis of disease (average = 16.3 months, range = 3-26 months prior to diagnosis), suggesting that elevated serum p21 levels may be a useful marker for earlier detection in a significant percentage of respiratory malignancies. Finally, elevated serum levels of PDGF-related protein were detected significantly more frequently in advanced pneumoconiosis cases (ILO radiographic classification of 2/1 or greater) than in less advanced cases (80{\%} vs. 41.9{\%}; p = 0.016), and there was a tendency for these PDGF-positive patients to have progression of their disease (68.2{\%} vs. 41.7{\%}; p = 0.065), suggesting that elevated serum PDGF levels may be a marker for the development of severe and progressive pneumoconioses.",
author = "Brandt-Rauf, {P. W.} and S. Smith and K. Hemminki and H. Koskinen and H. Vainio and H. Niman and J. Ford",
year = "1992",
language = "English (US)",
volume = "50",
pages = "881--885",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Serum oncoproteins and growth factors in asbestosis and silicosis patients

AU - Brandt-Rauf, P. W.

AU - Smith, S.

AU - Hemminki, K.

AU - Koskinen, H.

AU - Vainio, H.

AU - Niman, H.

AU - Ford, J.

PY - 1992

Y1 - 1992

N2 - Levels of 9 different oncoproteins and growth factors were assayed by immunoblotting with monoclonal antibodies in 91 serum samples collected between March 1983 and August 1987 from 46 pneumoconiosis patients (36 asbestosis, 10 silicosis) at high risk for the development of cancer. Follow-up of these patients through June 1991 showed that 18 had developed cancer (11 lung, 2 pleural mesothelioma, 2 transitional-cell carcinomas of the urinary bladder, 1 osteosarcoma, 1 non-Hodgkin's lymphoma, 1 adenocarcinoma of the gallbladder). Increased serum levels of ras oncogene-related protein (p21) were found in 7 of the 18 patients who developed cancer (5 lung, 2 pleural mesothelioma) versus 2 of the 28 patients without cancer, a statistically significant difference (p = 0.012). In addition, 6 of the 7 p21-positive cancer cases had positive serum samples prior to clinical diagnosis of disease (average = 16.3 months, range = 3-26 months prior to diagnosis), suggesting that elevated serum p21 levels may be a useful marker for earlier detection in a significant percentage of respiratory malignancies. Finally, elevated serum levels of PDGF-related protein were detected significantly more frequently in advanced pneumoconiosis cases (ILO radiographic classification of 2/1 or greater) than in less advanced cases (80% vs. 41.9%; p = 0.016), and there was a tendency for these PDGF-positive patients to have progression of their disease (68.2% vs. 41.7%; p = 0.065), suggesting that elevated serum PDGF levels may be a marker for the development of severe and progressive pneumoconioses.

AB - Levels of 9 different oncoproteins and growth factors were assayed by immunoblotting with monoclonal antibodies in 91 serum samples collected between March 1983 and August 1987 from 46 pneumoconiosis patients (36 asbestosis, 10 silicosis) at high risk for the development of cancer. Follow-up of these patients through June 1991 showed that 18 had developed cancer (11 lung, 2 pleural mesothelioma, 2 transitional-cell carcinomas of the urinary bladder, 1 osteosarcoma, 1 non-Hodgkin's lymphoma, 1 adenocarcinoma of the gallbladder). Increased serum levels of ras oncogene-related protein (p21) were found in 7 of the 18 patients who developed cancer (5 lung, 2 pleural mesothelioma) versus 2 of the 28 patients without cancer, a statistically significant difference (p = 0.012). In addition, 6 of the 7 p21-positive cancer cases had positive serum samples prior to clinical diagnosis of disease (average = 16.3 months, range = 3-26 months prior to diagnosis), suggesting that elevated serum p21 levels may be a useful marker for earlier detection in a significant percentage of respiratory malignancies. Finally, elevated serum levels of PDGF-related protein were detected significantly more frequently in advanced pneumoconiosis cases (ILO radiographic classification of 2/1 or greater) than in less advanced cases (80% vs. 41.9%; p = 0.016), and there was a tendency for these PDGF-positive patients to have progression of their disease (68.2% vs. 41.7%; p = 0.065), suggesting that elevated serum PDGF levels may be a marker for the development of severe and progressive pneumoconioses.

UR - http://www.scopus.com/inward/record.url?scp=0026523003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026523003&partnerID=8YFLogxK

M3 - Article

C2 - 1313398

AN - SCOPUS:0026523003

VL - 50

SP - 881

EP - 885

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -